Buchumschlag

NOAC monotherapy in patients with concomitant indications for oral anticoagulation undergoing transcatheter aortic valve implantation

AimsAntithrombotic therapy after transcatheter aortic valve implantation (TAVI) is highly controversial and guideline recommendations are not evidence based. We assessed efficacy and safety of non-vitamin K antagonist oral anticoagulant (NOAC) monotherapy in patients with concomitant indications for...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Geis, Nicolas (VerfasserIn) , Kiriakou, Christina (VerfasserIn) , Chorianopoulos, Emmanuel (VerfasserIn) , Katus, Hugo (VerfasserIn) , Bekeredjian, Raffi (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 11 April 2018
In: Clinical research in cardiology
Year: 2018, Jahrgang: 107, Heft: 9, Pages: 799-806
ISSN:1861-0692
DOI:10.1007/s00392-018-1247-x
Online-Zugang:Verlag, Volltext: https://doi.org/10.1007/s00392-018-1247-x
Volltext
Verfasserangaben:Nicolas A. Geis, Christina Kiriakou, Emmanuel Chorianopoulos, Lorenz Uhlmann, Hugo A. Katus, Raffi Bekeredjian
Beschreibung
Zusammenfassung:AimsAntithrombotic therapy after transcatheter aortic valve implantation (TAVI) is highly controversial and guideline recommendations are not evidence based. We assessed efficacy and safety of non-vitamin K antagonist oral anticoagulant (NOAC) monotherapy in patients with concomitant indications for OAC undergoing TAVI.MethodsAmong more than 1300 TAVI patients since 2008, 154 patients were identified who received postinterventional NOAC monotherapy. Outcomes were compared to 172 patients treated with vitamin K antagonist (VKA) monotherapy. Thromboembolic as well as bleeding complications were analysed for 6 months after TAVI.ResultsDespite high CHA2DS2-Vasc (4.6 ± 1.2), HEMORR2HAGES (4.7 ± 1.9) and HASBLED (2.7 ± 0.8) scores only three major/life-threatening bleedings and four thromboembolic events occurred after NOAC therapy had been initiated post-TAVI. 12 patients (7.8%) died within 6 months after the procedure. Compared to patients being treated with VKA monotherapy, analysis of a combined end-point of post-procedural death, stroke, embolism and severe bleeding revealed no significant differences (17/154 vs. 14/172; p = 0.45).ConclusionsThe results of this study suggest that NOAC therapy without additional antiplatelet treatment is effective and safe in patients with concomitant indications for OAC undergoing TAVI.
Beschreibung:Gesehen am 02.08.2019
Beschreibung:Online Resource
ISSN:1861-0692
DOI:10.1007/s00392-018-1247-x

Ähnliche Einträge